文献速递疼痛医学

PTAC对小鼠神经病理性疼痛模型的镇痛作用

The Analgesic Effects of (5R,6R)6-(3-Propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1] Octane on a Mouse Model of Neuropathic Pain.
PubMed 文献 · Anesth Analg · 2017-01-01

研究在C57BL/6小鼠左侧腓总神经结扎诱导的神经病理性疼痛模型中,系统或ACC局部给予毒蕈碱M2/M4激动剂PTAC,观察机械缩足阈值、静态负重平衡及条件位置偏爱,并检测纹状体、ACC和腹侧被盖区M1/M2表达。PTAC腹腔注射可提高神经损伤后早期和晚期缩足阈值并再平衡后肢负重,但未诱导条件位置偏爱;相同剂量下D3-5镇痛持续时间长于D14-16,可能与脑区M2和M1下调有关。

要点

  • PTAC腹腔注射可改善神经损伤小鼠的机械痛敏和负重失衡。
  • PTAC未在条件位置偏爱中诱导奖赏效应。
  • 相同剂量下早期镇痛持续时间长于晚期,可能与M2/M1下调有关。

核心结论

  • PTAC对神经损伤诱导的神经病理性疼痛具有镇痛作用。

研究设计与样本

  • 雄性C57BL/6小鼠行左侧腓总神经结扎诱导神经病理性疼痛,系统或前扣带皮层给予PTAC,测量机械缩足阈值和静态负重平衡,评估条件位置偏爱,并用Western blotting检测纹状体、ACC和腹侧被盖区M1和M2表达。

主要发现

  • PTAC腹腔注射在神经损伤后早期提高缩足阈值:0.05 mg/kg平均差(95%CI)0.19(0.05-0.32),0.10 mg/kg为0.34(0.22-0.46)。
  • PTAC腹腔注射在神经损伤后晚期提高缩足阈值:0.05 mg/kg平均差(95%CI)0.45(0.39-0.50),0.1 mg/kg为0.44(0.37-0.51)。
  • PTAC再平衡后肢负重:左/右比值给药前0.56±0.03,0.05 mg/kg为1.00±0.04,0.10 mg/kg为0.99±0.03。
  • PTAC未诱导条件位置偏爱:0.05 mg/kg和0.2 mg/kg双因素方差分析P>.05。
  • 相同剂量下D3-5的镇痛效果持续时间长于D14-16,可能与检测脑区M2和M1下调有关。

临床怎么用

  • PTAC的镇痛效应在小鼠神经病理性疼痛模型中得到验证,提示毒蕈碱M2/M4受体可能作为慢性疼痛治疗的候选靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Both pharmacologic and genetic approaches have been used to study the involvement of the muscarinic acetylcholine system in the regulation of chronic pain. Previous studies suggest that the M2 and M4 subtypes of muscarinic acetylcholine receptors (mAChRs) are important targets for the development of chronic pain. (5R,6R)6-(3-Propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1] octane (PTAC) has agonist effects on muscarinic M2 and M4 receptors and antagonist effects on muscarinic M1, M3, and M5 receptors. However, its analgesic effects have been less studied. METHODS: Male C57B L/6 mice were anesthetized, and left common peroneal nerve (CPN) ligation was performed to induce neuropathic pain. Before and after the application of PTAC systemically or specifically to the anterior cingulate cortex (ACC), the withdrawal thresholds to mechanical stimulation and static weight balance were measured, and the effects of PTAC on the conditioned place preference (CPP) were further evaluated. Western blotting was used to examine the expression of M1 and M2 in the striatum, ACC, and ventral tegmental area. RESULTS: The application of PTAC ([i.p.] intraperitoneal injection) increased the paw withdraw threshold in both the early (0.05 mg/kg, mean difference [95% confidence interval, CI]: 0.19 [0.05-0.32]; 0.10 mg/kg: mean difference [95% CI]: 0.34 [0.22-0.46]) and the late phases (0.05 mg/kg: mean difference [95% CI]: 0.45 [0.39-0.50]; 0.1 mg/kg: mean difference [95% CI]: 0.44 [0.37-0.51]) after nerve injury and rebalanced the weight distribution on the hind paws of mice (L/R ratio: before, 0.56 ± 0.03. 0.05 mg/kg, 1.00 ± 0.04, 0.10 mg/kg, 0.99 ± 0.03); however, it failed to induce place preference in the CPP (0.05 mg/kg, 2-way analysis of variance, P > .05; 0.2 mg/kg, 2-way analysis of variance, P > .05,). At the same doses, the analgesic effects at D3-5 lasted longer than the effects at D14-16. This may be due to the down-regulation of the M2 and M1 in tested brain regions. CONCLUSIONS: These observations suggested that PTAC has analgesic effects on the neuropathic pain induced by nerve injury.

来源:Anesth Analg,查看原文。版权归原作者所有。

引用

  1. Wang YJ, Zuo ZX, Zhang M, et al. The Analgesic Effects of (5R,6R)6-(3-Propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1] Octane on a Mouse Model of Neuropathic Pain. Anesth Analg. 2017. PMID: 28002166. doi:10.1213/ANE.0000000000001755

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。